TITLE

Tiotropium reduced exacerbations and health resource use in COPD: COMMENTARY

AUTHOR(S)
Mahler, Donald A.
PUB. DATE
November 2003
SOURCE
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p64
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Researchers V. Brusasco and colleagues have focused on three outcomes exacerbations, health-related quality of life (HRQL) and dyspnea of the four important clinical outcomes in evaluating pharmacotherapy for chronic obstructive pulmonary disease (COPD). The requirement to stop inhaled anticholinergic therapy and long-acting β-agonists before enrollment probably contributed to withdrawals and shows the challenges of long-term trials in symptomatic and impaired patients. The delayed time to first exacerbation and the fewer number of COPD exacerbations observed with tiotropium can be expected to have a major effect on reducing hospitalizations and overall health care costs. Although both tiotropium and salmeterol improved HRQL and dyspnea, neither agent achieved the minimal important difference established for the SGRQ compared with placebo. Compared with placebo, salmeterol was efficacious in some randomized controlled trials, but this and other trials failed to show a consistent benefit.
ACCESSION #
11533495

 

Related Articles

  • Tiotropium reduced exacerbations and health resource use in COPD.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p64 

    This article discusses whether tiotropium is more effective than salmeterol or placebo in reducing exacerbations and health resource use in patients with chronic obstructive pulmonary disease (COPD). Patients who have received tiotropium had fewer COPD exacerbations and exacerbation-days per...

  • Add-on omalizumab improves QOL in severe allergic asthma.  // PharmacoEconomics & Outcomes News;12/16/2006, Issue 518, p9 

    The article reports on the improvement of quality of life (QOL) of patients with severe allergic asthma after taking add-on therapy with omalizumab according to a study. 2548 patients were used for the study. Using the Juniper Asthma QOL Questionnaire, patients who received omalizumab showed...

  • LUNG ALERT: ambroxol and reduction of COPD exacerbations. Perera, W. R. // Thorax;Apr2004, Vol. 59 Issue 4, p336 

    This study examined the effect of ambroxol in preventing acute exacerbations of Chronic Obstrctive Pulmonary Diseases (COPD). 242 patients with at least a history of chronic bronchitis, abnormal chest auscultation and at least one exacerbation in the previous year were recruited and randomised...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease: COMMENTARY. Rees, P. John // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article covers a wide range of treatments for chronic obstructive pulmonary disease (COPD). Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been the absence of large, long-term studies, unlike the field...

  • Glycophosphopeptical benefit in COPD.  // PharmacoEconomics & Outcomes News;5/21/2005, Issue 478, p13 

    Discusses research being done on the effect of the treatment with the immunomodulator AM3 on the health-related quality of life of patients with chronic obstructive pulmonary disease. Reference to a study by L. J. Crofford et al, published in the April 2005 issue of the "Arthritis and...

  • Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Størdal, K.; Johannesdottir, G. B.; Bentsen, B. S.; Knudsen, P. K.; Carlsen, K. C. L.; Closs, O.; Handeland, M.; Holm, H. K.; Sandvik, L. // Archives of Disease in Childhood;Sep2005, Vol. 90 Issue 9, p956 

    Background: Epidemiological studies have shown an association between gastro-oesophageal reflux disease (GORD) and asthma, and oesophageal acid perfusion may cause bronchial constriction. However, no causative relation has been proven. Aim: To assess whether acid suppression would lead to...

  • GERD, clinical profile and management. Priyanka, D. V. // New Indian Journal of Surgery;Oct2011, Vol. 2 Issue 4, p247 

    GERD is the most common gastrointestinal disorders encountered in clinical practice. It is more than Heartburn, which is one of the several complaints. Patients can also suffer from regurgitation, nausea, cough , sore throat, hiccups, chest pain, sleep disturbances etc... which not only...

  • Acute Exacerbations of Chronic Bronchitis in Elderly Patients: Pathogenesis, Diagnosis and Management. Hayes Jr., Don; Meyer, Keith C. // Drugs & Aging;2007, Vol. 24 Issue 7, p555 

    Chronic bronchitis (CB) is a disorder that is characterised by chronic mucus production. This disorder is called chronic obstructive pulmonary disease (COPD) when airflow obstruction is present. The majority of patients with COPD, which often goes undiagnosed or inadequately treated in the...

  • Montelukast provides clinical benefits, QOL boost in COPD.  // PharmacoEconomics & Outcomes News;6/18/2005, Issue 480, p17 

    Discusses research being done on the effect of montelukast on the respiratory function and quality of life of patients with moderate-to-severe chronic obstructive pulmonary disease. Reference to a study by P. Celik, A. Sakar et al, published in the April 2005 issue of the periodical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics